Adverse clinical outcomes related to SARS-CoV-2 infection among liver transplant (LTx) recipients remain undefined . We performed a meta-analysis to determine the pooled prevalence of outcomes among hospitalized LTx recipients with COVID-19 . A database search of literature published between December 1 , 2019 - November 20 , 2020, was performed per PRISMA guidelines . Twelve studies comprising 517 hospitalized LTx recipients with COVID-19 were analyzed . Common presenting symptoms were fever (71 %), cough (62 %), dyspnea (48 %), and diarrhea (28 %). Approximately 77% (95% CI , 61% -93 %) of LTx recipients had a history of liver cirrhosis . The most prevalent co-morbidities were hypertension (55 %), diabetes (45 %) and cardiac disease (21 %). In-hospital mortality was 20% (95% CI , 13% -28 %) and rose to 41% (95% CI , 19% -63 %) (P value <0.00) with ICU admission . Additional subgroup analysis demonstrated a higher mortality risk in the elderly (> 60-65 years) (OR 4.26; 95% CI , 2.14-8.49). There was no correlation in respect to sex or time since transplant . In summary, LTx recipients with COVID-19 had a high prevalence of dyspnea and gastrointestinal symptoms . In-hospital mortality was comparable to non-transplant populations with similar co-morbidities but appeared to be less than what is reported elsewhere for cirrhotic patients (26-40 %). Importantly, the observed high case-fatality in the elderly could be due to age-associated co-morbidities.